
Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.

Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.

Explore expert insights on managing myelofibrosis, focusing on anemia, JAK inhibitors, and enhancing patient care for better outcomes.

BV-R2 combination shows survival benefit across high-risk subgroups.

The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

Pharmacists will play a significant role in TKI adherence rates among patients.